OLIGONUCLEOTIDE THERAPEUTICS
2024
Boston, June 21, 2024

Welcome to hubXchange’s Boston Oligonucleotide Therapeutics 2024, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in oligonucleotide therapeutics.

Discussion topics will cover New Modalities, Oligonucleotide Discovery, Manufacturing and Drug Delivery.

Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.

Venue: Woburn Hilton Hotel, 2 Forbes Road, Woburn, MA, 01801, US

SNAPSHOTS OF DISCUSSION TOPICS

  • New formats / chemical modifications for antisense therapeutics
  • Nucleic acid therapeutics optimization through in vitro and in vivo assays.
  • How to speed up oligonucleotide drug candidates selection
  • Emerging opportunities for liver-targeting and extrahepatic areas.

  • Downstream manufacturing challenges for synthetic oligonucleotides.
  • Novel methodologies to manufacture Oligonucleotides.
  • Using Lipid Nanoparticles (LNPs) as vehicles for intracellular delivery of nucleotide-based therapeutics.

Full Xchange Agenda

Click on each track for detailed agenda

New Modalities

Time
Titles and Bullets
Facilitator
08:00 – 08:30
Registration 
08:30 – 09:00

Opening Address & Keynote Presentation (TOPIC TBC) by ChemGenes

09:05 – 10:05

New formats / chemical modifications for antisense therapeutics

  • In vivo efficacy
  • Safety Issues
  • Biodistribution
  • Tissue/cell-targeted delivery

 

Vinod has more than a decade of experience in the RNA medicine field from Pharma and Biotech, where he led multiple ASO drugs into clinical trials. Vinod currently serves as a board director for Aldebaran therapeutics, a company focused on developing best-in-class precision ASO therapeutics for Ocular indications. He also leads the RNA Medicine department at Alloy Therapeutics. Previously, he headed the ASO therapeutic programs in Leal Therapeutics (VP, Head of Nucleic Acid Therapeutics) and Eisai (Director, Head of ASO Therapeutics).

Vinod Vathipadiekal
10:10 – 10:40
1-2-1 Meetings/Networking Break
10:45 – 11:15
1-2-1 Meetings / Networking Break
11:15 – 11:25
Morning Refreshments
11:25 – 12:25

Nitto-Avecia Roundtable Discussion

12:25 – 13:25

Networking Lunch

13:25 – 13:55

Spotlight Presentation by Vazyme

 

14:00 – 14:30
1-2-1 Meetings / Networking Break
14:35 – 15:05
1-2-1 Meetings / Networking Break

15:05 – 15:35

Poster Session: Thiophosphoramidate Morpholino Oligonucleotides (TMOs): A Novel Class of PMOs compatible With Conventional Automated Oligonucleotide Synthesis.

15:40 – 16:40

Nucleic acid therapeutics optimization through in vitro and in vivo assays.

16:40– 17:40
Evening Drinks Reception

Partners

Oligonucleotide Therapeutics | Boston 2024
Register